Subtopic Deep Dive
MYCN Amplification in Neuroblastoma
Research Guide
What is MYCN Amplification in Neuroblastoma?
MYCN amplification is a genomic alteration in approximately 25% of neuroblastoma cases that serves as a key prognostic marker for high-risk disease and drives aggressive tumor behavior.
MYCN amplification correlates with poor survival outcomes and guides risk stratification in neuroblastoma patients (Huang and Weiss, 2013, 626 citations). Found in ∼25% of cases, it originates from neural crest cells and influences therapy selection (Molenaar et al., 2012, 868 citations). Over 10 key papers from 1997-2021 document its role, with Matthay et al. (1999, 1892 citations) establishing intensive therapies for high-risk cases.
Why It Matters
MYCN amplification status determines risk group assignment in Children's Oncology Group protocols, directing intensive chemotherapy, immunotherapy, and retinoids for high-risk neuroblastoma (Irwin et al., 2021, 431 citations; Matthay et al., 1999). It predicts worse outcomes when combined with 1p or 11q deletions, enabling personalized treatment like ch14.18 antibody therapy that improved event-free survival (Yu et al., 2010, 1746 citations; Attiyeh et al., 2005, 569 citations). Functional studies confirm MYCN drives tumorigenesis, supporting targeted Aurora A inhibition (Otto et al., 2009, 558 citations).
Key Research Challenges
Targeting Undruggable MYCN
MYCN lacks a ligand-binding pocket, complicating direct inhibition despite its role as a transcriptional driver (Huang and Weiss, 2013). Indirect strategies via Aurora A stabilization show promise but face resistance in amplified tumors (Otto et al., 2009). Transgenic models confirm MYCN sufficiency for neuroblastoma but highlight need for pathway-specific drugs (Weiss, 1997).
Heterogeneous Risk Stratification
MYCN integrates with age, stage, and ploidy for COG risk groups, but age cutoffs above 365 days refine predictions (London et al., 2005, 581 citations). 11q/1p deletions interact with MYCN to worsen prognosis, requiring multi-omic integration (Attiyeh et al., 2005). Recent revisions incorporate histopathology for precision (Irwin et al., 2021).
Chromothripsis in MYCN Tumors
Sequencing reveals chromothripsis and neuritogenesis defects alongside MYCN amplification in aggressive cases (Molenaar et al., 2012). These structural variants complicate genomic profiling and therapy response. Functional validation lags behind identification.
Essential Papers
Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-<i>cis</i>-Retinoic Acid
Katherine K. Matthay, Judith G. Villablanca, Robert C. Seeger et al. · 1999 · New England Journal of Medicine · 1.9K citations
Treatment with myeloablative therapy and autologous bone marrow transplantation improved event-free survival among children with high-risk neuroblastoma. In addition, treatment with 13-cis-retinoic...
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Alice L. Yu, Andrew L. Gilman, M. Fevzi Özkaynak et al. · 2010 · New England Journal of Medicine · 1.7K citations
Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the...
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes
Jan J. Molenaar, Jan Köster, Danny A. Zwijnenburg et al. · 2012 · Nature · 868 citations
Neuroblastoma is a childhood tumour of the peripheral sympathetic nervous system. The pathogenesis has for a long time been quite enigmatic, as only very few gene defects were identified in this of...
Targeted expression of MYCN causes neuroblastoma in transgenic mice
William A. Weiss · 1997 · The EMBO Journal · 864 citations
Neuroblastoma and MYCN
Miller Huang, William A. Weiss · 2013 · Cold Spring Harbor Perspectives in Medicine · 626 citations
Neuroblastoma, the most common extracranial solid tumor of childhood, is thought to originate from undifferentiated neural crest cells. Amplification of the MYC family member, MYCN, is found in ∼25...
Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group
Wendy B. London, R P Castleberry, Katherine K. Matthay et al. · 2005 · Journal of Clinical Oncology · 581 citations
Purpose In the Children's Oncology Group, risk group assignment for neuroblastoma is critical for therapeutic decisions, and patients are stratified by International Neuroblastoma Staging System st...
Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma
Edward F. Attiyeh, Wendy B. London, Yaël P. Mossé et al. · 2005 · New England Journal of Medicine · 569 citations
Unb11q LOH and 1p36 LOH are independently associated with a worse outcome in patients with neuroblastoma.
Reading Guide
Foundational Papers
Start with Weiss (1997, 864 citations) for MYCN transgenic proof-of-concept, then Huang and Weiss (2013, 626 citations) for clinical correlation, and Matthay et al. (1999, 1892 citations) for high-risk therapy benchmarks.
Recent Advances
Irwin et al. (2021, 431 citations) updates COG risk system with MYCN; Molenaar et al. (2012, 868 citations) details genomic context.
Core Methods
FISH/array CGH for amplification detection; transgenic mice for functional studies (Weiss, 1997); sequencing for chromothripsis (Molenaar et al., 2012); COG risk models integrating MYCN, age, ploidy (London et al., 2005).
How PapersFlow Helps You Research MYCN Amplification in Neuroblastoma
Discover & Search
Research Agent uses searchPapers and citationGraph to map MYCN literature from Matthay et al. (1999) central node, revealing 1892 citations linking to Weiss (1997) transgenic models and Otto et al. (2009) Aurora A studies. exaSearch uncovers recent COG updates like Irwin et al. (2021); findSimilarPapers expands from Huang and Weiss (2013) to 50+ related amplification papers.
Analyze & Verify
Analysis Agent applies readPaperContent to extract MYCN amplification rates from Molenaar et al. (2012), then verifyResponse with CoVe cross-checks claims against Attiyeh et al. (2005). runPythonAnalysis processes survival data from London et al. (2005) via pandas for hazard ratios, with GRADE grading high-risk stratification evidence as A-level.
Synthesize & Write
Synthesis Agent detects gaps in MYCN-Aurora A inhibitors post-Otto et al. (2009), flagging contradictions in risk models. Writing Agent uses latexEditText for risk stratification tables, latexSyncCitations for 10+ papers, and latexCompile for manuscripts; exportMermaid diagrams MYCN pathway networks from Weiss (1997).
Use Cases
"Run survival analysis on MYCN amplified vs non-amplified neuroblastoma cohorts from COG studies."
Research Agent → searchPapers('MYCN neuroblastoma COG') → Analysis Agent → runPythonAnalysis(pandas on Matthay 1999 and London 2005 survival data) → matplotlib Kaplan-Meier plots and hazard ratios output.
"Draft LaTeX review section on MYCN-driven therapies with citations."
Synthesis Agent → gap detection in Huang 2013 → Writing Agent → latexEditText('MYCN amplification therapies') → latexSyncCitations(10 papers) → latexCompile → PDF with risk tables.
"Find code for MYCN expression analysis in neuroblastoma datasets."
Research Agent → paperExtractUrls(Molenaar 2012) → paperFindGithubRepo → githubRepoInspect → Code Discovery workflow outputs R scripts for chromothripsis detection.
Automated Workflows
Deep Research workflow scans 50+ MYCN papers via citationGraph from Weiss (1997), generating structured reports on risk stratification (Irwin 2021). DeepScan's 7-step chain verifies MYCN claims in Otto et al. (2009) with CoVe checkpoints and Python stats on survival. Theorizer builds hypotheses on MYCN-chromothripsis interactions from Molenaar et al. (2012).
Frequently Asked Questions
What defines MYCN amplification in neuroblastoma?
MYCN amplification occurs in ∼25% of cases, detected via FISH or array CGH, marking high-risk disease (Huang and Weiss, 2013).
What methods study MYCN's role?
Transgenic mouse models overexpress MYCN to induce neuroblastoma (Weiss, 1997); sequencing identifies co-occurring chromothripsis (Molenaar et al., 2012).
What are key papers on MYCN?
Huang and Weiss (2013, 626 citations) reviews biology; Matthay et al. (1999, 1892 citations) treats high-risk cases; Otto et al. (2009, 558 citations) links to Aurora A.
What open problems exist?
Direct MYCN inhibitors remain elusive; integrating MYCN with 1p/11q deletions for ultra-high-risk groups needs refinement (Attiyeh et al., 2005; Irwin et al., 2021).
Research Neuroblastoma Research and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching MYCN Amplification in Neuroblastoma with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers